secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2022-05-02T23:59:59+00:00
Accession:  0001193125-22-136748
Event type: other
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Magenta Therapeutics enters amended employment agreements with two executives
-----------------------------------------------------------------------------

- Thomas Beetham (CLO) base salary $435,000, target incentive 40% of base, amended severance details.
- David Nichols (CTO) base salary $362,000, target incentive 40% of base, amended severance details.
- Severance: 0.75x base plus pro-rata target outside change in control; 1x base plus 100% target and accelerated vesting within change in control period.
- Agreements effective May 2, 2022, supersede prior employment agreements.
- Standard COBRA subsidies included; subject to release and noncompetition covenant.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000119312522136748/0001193125-22-136748-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000119312522136748/d337873d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-136748

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer